Roivant Sciences Ltd. (ROIV)
NASDAQ:ROIV
Want to see ROIV full AI Analyst Report?
Top Page
Roivant Sciences
(NASDAQ:ROIV)
Select Model
Select Model
Rating:68Neutral
Price Target:
$35.00
▲(17.33% Upside)
Action:Reiterated
Date:05/21/26
ROIV scores positively on momentum and pipeline/catalyst setup supported by strong liquidity (cash position and the Moderna settlement), but the overall score is held back by weak current financial performance (large losses, declining revenue, and heavy free-cash-flow burn) and limited valuation support given negative earnings.
Positive Factors
Strong balance sheet and settlement proceeds
Roivant's sizable cash position plus the $2.25B Moderna settlement materially extends runway and strategic optionality. Low leverage reduces refinancing/dilution risk, enabling sustained R&D and commercial investments, M&A flexibility, or shareholder returns over the next several quarters.
Negative Factors
Persistent cash burn and weak cash generation
Despite large cash reserves, Roivant's consistent negative operating and free cash flows erode runway absent milestone receipts or asset monetization. Ongoing burn raises dependency on settlements, partnerships or capital markets, constraining long-term capital allocation and heightening dilution risk if deals miss expectations.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet and settlement proceeds
Roivant's sizable cash position plus the $2.25B Moderna settlement materially extends runway and strategic optionality. Low leverage reduces refinancing/dilution risk, enabling sustained R&D and commercial investments, M&A flexibility, or shareholder returns over the next several quarters.
Read all positive factors
Roivant Sciences (ROIV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$21.28B
Dividend YieldN/A
Average Volume (3M)6.08M
Price to Earnings (P/E)―
Beta (1Y)0.79
Revenue Growth-89.16%
EPS Growth-84.69%
CountryUS
Employees908
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.45
Shares Outstanding719,270,400
10 Day Avg. Volume8,340,755
30 Day Avg. Volume6,083,568
Financial Highlights & Ratios
PEG Ratio-0.81
Price to Book (P/B)4.25
Price to Sales (P/S)2326.88
P/FCF Ratio-25.34
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue2.44K
Enterprise Value/Gross Profit2.89K
Enterprise Value/Ebitda-15.74
Forecast
1Y Price Target
$37.83Price Target Upside26.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.26
Revenue Forecast (FY)$76.52M
Roivant Sciences Business Overview & Revenue Model
Company Description
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, h...
How the Company Makes Money
Roivant makes money primarily through (1) commercial product revenue from medicines marketed by its subsidiaries (where applicable), (2) collaboration income such as upfront payments, milestone payments, and reimbursement/other collaboration reven...
Roivant Sciences Earnings Call Summary
Earnings Call Date:May 20, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Aug 17, 2026
Earnings Call Sentiment Positive
The call highlighted multiple strong clinical signals (notably the robust open-label 1402 RA responses and mosli hemodynamic activity), solid financial backing (cash of $4.3B and a $2.25B Moderna settlement), and rapid execution across trials and commercial prep. Key risks were acknowledged: interpretability limitations from open-label data, potential difficulty meeting the randomized withdrawal primary endpoint for 1402, some program failures (bitokamab), pending biomarker analyses, and competitive/ regulatory hurdles in indications like CLE and PH-ILD. On balance, the pipeline momentum, cash position, and high-impact data presented outweigh the noted challenges, though important uncertainties remain that will require follow-up data and regulatory feedback.Positive Updates
Strong IMVT-1402 (FcRn) Open-Label RA Results (Period 1)
Preliminary open-label data from the 1402 DTRA study showed high response rates in a heavily refractory RA population: ACR20 ~73%, ACR50 >50%, ACR70 >33%. Study enrolled ~165 evaluable patients with high baseline disease activity (DAS28-CRP ~6.1).
Negative Updates
Randomized Withdrawal (Period 2) Endpoint Risk for 1402
Period 2 primary endpoint is loss of ACR20 over a 12-week randomized withdrawal which may be challenging given deep responses (ACR50/70) observed in Period 1; the short 12-week window and deep responses could reduce the chance of achieving statistical separation despite a meaningful drug effect.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong IMVT-1402 (FcRn) Open-Label RA Results (Period 1)
Preliminary open-label data from the 1402 DTRA study showed high response rates in a heavily refractory RA population: ACR20 ~73%, ACR50 >50%, ACR70 >33%. Study enrolled ~165 evaluable patients with high baseline disease activity (DAS28-CRP ~6.1).
Read all positive updates
Company Guidance
Management gave timing and quantitative guidance across programs: brepocitinib is planned to launch in dermatomyositis by the end of September (pending FDA), a cutaneous sarcoidosis Phase III is expected to start this year, NIU Phase III top‑line and CLE POC top‑line data are expected in H2 2026, and 1402 Period‑1 (≈165 evaluable patients, 16 weeks at 600 mg) showed ~73% ACR20, >50% ACR50 and >33% ACR70 with ~65% of patients JAK‑experienced (107 patients); Period‑2 is a 12‑week randomized withdrawal (600 mg vs 300 mg vs placebo) assessing loss of ACR20. Mosliciguat (mosli) FOCUS enrolled 135 patients (target 120), mean baseline PVR 7.1 WU and mean mPAP 39.3, >95% titrated to 4 mg, and Phase I (n=170: 132 healthy volunteers, 38 PH patients) showed mean PVR reductions >30% (peak ≈38%), cGMP increases, cardiac output up to +25% and an ~40‑hour half‑life. Financially, Roivant reported $4.3B cash on 3/31 with no debt and a $2.25B Moderna settlement (first $950M upfront expected in July).Roivant Sciences Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
74
Positive
Cash Flow
18
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 8.26M | 29.05M | 32.71M | 31.53M | 55.29M |
| Gross Profit | 6.97M | 28.14M | 31.11M | 28.50M | 46.32M |
| EBITDA | -1.28B | -1.10B | -802.89M | -790.16M | -910.77M |
| Net Income | -299.77M | -171.98M | 4.35B | -1.01B | -845.26M |
Balance Sheet | |||||
| Total Assets | 5.73B | 5.44B | 7.22B | 2.39B | 2.59B |
| Cash, Cash Equivalents and Short-Term Investments | 4.30B | 4.89B | 6.54B | 1.68B | 2.06B |
| Total Debt | 107.44M | 100.17M | 499.75M | 481.40M | 283.89M |
| Total Liabilities | 435.63M | 249.74M | 773.95M | 782.02M | 523.70M |
| Stockholders Equity | 4.53B | 4.69B | 5.97B | 1.16B | 1.66B |
Cash Flow | |||||
| Free Cash Flow | -758.56M | -844.05M | -766.65M | -856.08M | -695.16M |
| Operating Cash Flow | -750.35M | -839.45M | -765.27M | -843.39M | -677.73M |
| Investing Cash Flow | -682.33M | -1.77B | 5.20B | -44.27M | 303.30M |
| Financing Cash Flow | 134.24M | -1.22B | 419.36M | 499.46M | 306.79M |
Roivant Sciences Technical Analysis
Positive
29.83
Price Trends
28.58
Positive
27.07
Positive
22.32
Positive
Market Momentum
0.44
Negative
54.69
Neutral
39.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ROIV, the sentiment is Positive. The current price of 29.83 is above the 20-day moving average (MA) of 29.28, above the 50-day MA of 28.58, and above the 200-day MA of 22.32, indicating a bullish trend. The MACD of 0.44 indicates Negative momentum. The RSI at 54.69 is Neutral, neither overbought nor oversold. The STOCH value of 39.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ROIV.
Roivant Sciences Risk Analysis
Roivant Sciences disclosed 98 risk factors in its most recent earnings report. Roivant Sciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Roivant Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
83 Outperform | $8.14B | 23.09 | 126.27% | ― | 39.12% | -24.20% | |
75 Outperform | $7.15B | 149.08 | 7.50% | ― | 12.20% | -64.76% | |
72 Outperform | $14.91B | 494.02 | 0.71% | ― | 9.20% | -94.01% | |
68 Neutral | $21.28B | -69.99 | -6.85% | ― | -89.16% | -84.69% | |
62 Neutral | $7.53B | 72.33 | 5.49% | 0.54% | 0.17% | -15.73% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
ROIV
Roivant Sciences
29.99
19.00
172.88%
CORT
Corcept Therapeutics
69.49
-8.07
-10.40%
HALO
Halozyme
66.54
10.47
18.67%
JAZZ
Jazz Pharmaceuticals
236.49
128.42
118.83%
TECH
Bio-Techne
51.68
3.57
7.42%
Roivant Sciences Corporate Events
Business Operations and StrategyProduct-Related Announcements
Roivant Advances Brepocitinib Program, Refocuses Autoimmune Portfolio
Negative
Apr 2, 2026
On April 2, 2026, Roivant announced that its subsidiary Priovant had launched a seamless Phase 2b/3 clinical program of brepocitinib in lichen planopilaris, a rare, highly morbid inflammatory scalp disorder with no FDA-approved therapies and an es...
Business Operations and StrategyStock BuybackLegal Proceedings
Roivant Subsidiary Reaches Major Global Patent Settlement
Positive
Mar 3, 2026
On March 3, 2026, Roivant’s subsidiary Genevant Sciences and partner Arbutus Biopharma reached a $2.25 billion global settlement with Moderna to resolve all U.S. and international patent litigation over Moderna’s use of their lipid nan...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Roivant’s Priovant Unit Gains FDA Priority Review for Brepocitinib
Positive
Mar 3, 2026
On March 3, 2026, Roivant subsidiary Priovant Therapeutics said the U.S. Food and Drug Administration accepted its New Drug Application for brepocitinib to treat dermatomyositis and granted the filing Priority Review. The FDA set a Prescription Dr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.